Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
AgomAb Therapeutics, a Belgian biotech focused on TGFβ inhibitors for fibrotic diseases, is set to raise $200 million through its IPO, offering 12.5 million shares priced between $15 and $17. The company is also developing a preclinical candidate for liver cirrhosis.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.